- Theratechnologies (TSX:TH) is enrolling patients for a Phase 1 clinical trial across all five of its U.S. clinical sites
- The trial is examining the company’s lead drug in patients with advanced ovarian cancer
- A sixth site in Canada is finalizing its start-up activity
- Shares of Theratechnologies are up 4.65 per cent to C$1.35 as of 10:41 am ET
Theratechnologies (TSX:TH) has officially begun enrolling patients for a Phase 1 clinical trial of its lead drug in patients with advanced ovarian cancer.
In a news release, the Montreal-based biopharmaceutical company said patients are being enrolled in all five of its U.S. clinical sites, while a sixth Canadian clinical site is being finalized.
Called sudocetaxel zendusortide, the company’s drug conjugate candidate was developed out of its SORT1+ Technology and is currently linked to docetaxel, which is a commonly used cytoxic agent to treat cancers.
The SORT1+ Technology platform is a platform of proprietary peptides for cancer drug development that is targeting SORT1 receptors.
It is estimated that the SORT1 receptor is found in 40 per cent to 90 per cent of endometrial, ovarian, colorectal, triple-negative breast and pancreatic cancers.
Theratechnologies is focused on developing therapies addressing unmet medical needs.
Shares of Theratechnologies are up 4.65 per cent to C$1.35 as of 10:41 a.m. ET.
Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.